-
Je něco špatně v tomto záznamu ?
Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128]
H. Gogas, R. Dummer, PA. Ascierto, A. Arance, M. Mandalà, G. Liszkay, C. Garbe, D. Schadendorf, I. Krajsová, R. Gutzmer, V. Chiarion Sileni, C. Dutriaux, N. Yamazaki, C. Loquai, P. Queirolo, GJ. de Willem, AT. Sellier, J. Suissa, J. Murris, A....
Jazyk angličtina Země Velká Británie
Typ dokumentu tisková chyba
- Publikační typ
- tisková chyba MeSH
At Time of Research Pfizer Inc Boulder CO USA
Department of Dermatologic Oncology National Cancer Center Hospital Tokyo Japan
Department of Medical Oncology Isala Oncological Center Zwolle Netherlands
Eberhard Karls University Tuebingen Germany
German Cancer Consortium Heidelberg Germany
Hannover Medical School Hannover Germany
Hospital Clinic of Barcelona Barcelona Spain
Institute Gustave Roussy Villejuif France
Istituto Nazionale Tumori IRCCS Fondazione Pascale Napoli Italy
Massachusetts General Hospital Boston MA USA
National and Kapodistrian University of Athens Laikon Hospital Athens Greece
National Institute of Oncology Budapest Hungary
Oncology Institute of Veneto IRCCS Padua Italy
Ospedale Policlinico San Martino IRCCS Genoa Italy
Pierre Fabre Medicament Boulogne Billancourt France
Unit of Medical Oncology University of Perugia Perugia Italy
University Hospital Centre Bordeaux Hôpital Saint Andre´ Bordeaux France
University Hospital Essen Essen Germany
University Hospital Prague and Charles University 1st Medical Faculty Prague Czech Republic
University Hospital Zürich Skin Cancer Center Zürich Switzerland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22000991
- 003
- CZ-PrNML
- 005
- 20220112153443.0
- 007
- ta
- 008
- 220107s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejca.2021.10.002 $2 doi
- 035 __
- $a (PubMed)34756500
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Gogas, Helen $u National and Kapodistrian University of Athens, Laikon Hospital, Athens, Greece. Electronic address: helgogas@gmail.com
- 245 10
- $a Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128] / $c H. Gogas, R. Dummer, PA. Ascierto, A. Arance, M. Mandalà, G. Liszkay, C. Garbe, D. Schadendorf, I. Krajsová, R. Gutzmer, V. Chiarion Sileni, C. Dutriaux, N. Yamazaki, C. Loquai, P. Queirolo, GJ. de Willem, AT. Sellier, J. Suissa, J. Murris, A. Gollerkeri, C. Robert, KT. Flaherty
- 655 _2
- $a tisková chyba $7 D016425
- 700 1_
- $a Dummer, Reinhard $u University Hospital Zürich Skin Cancer Center, Zürich, Switzerland
- 700 1_
- $a Ascierto, Paolo A $u Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
- 700 1_
- $a Arance, Ana $u Hospital Clinic of Barcelona, Barcelona, Spain
- 700 1_
- $a Mandalà, Mario $u Unit of Medical Oncology, University of Perugia, Perugia, Italy
- 700 1_
- $a Liszkay, Gabriella $u National Institute of Oncology, Budapest, Hungary
- 700 1_
- $a Garbe, Claus $u Eberhard Karls University, Tuebingen, Germany
- 700 1_
- $a Schadendorf, Dirk $u University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany
- 700 1_
- $a Krajsová, Ivana $u University Hospital Prague and Charles University First Medical Faculty, Prague, Czech Republic
- 700 1_
- $a Gutzmer, Ralf $u Hannover Medical School, Hannover, Germany
- 700 1_
- $a Chiarion Sileni, Vanna $u Oncology Institute of Veneto IRCCS, Padua, Italy
- 700 1_
- $a Dutriaux, Caroline $u University Hospital Centre Bordeaux, Hôpital Saint-Andre´, Bordeaux, France
- 700 1_
- $a Yamazaki, Naoya $u Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan
- 700 1_
- $a Loquai, Carmen $u University Medical Center, Mainz, Germany
- 700 1_
- $a Queirolo, Paola $u Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy; Ospedale Policlinico San Martino IRCCS, Genoa, Italy
- 700 1_
- $a de Willem, Groot J $u Department of Medical Oncology, Isala Oncological Center, Zwolle, Netherlands
- 700 1_
- $a Sellier, Abir T $u Pierre Fabre Medicament, Boulogne-Billancourt, France
- 700 1_
- $a Suissa, Jeanne $u Pierre Fabre Medicament, Boulogne-Billancourt, France
- 700 1_
- $a Murris, Juliette $u Pierre Fabre Medicament, Boulogne-Billancourt, France
- 700 1_
- $a Gollerkeri, Ashwin $u At Time of Research: Pfizer Inc., Boulder, CO, USA
- 700 1_
- $a Robert, Caroline $u Institute Gustave Roussy, Villejuif, France
- 700 1_
- $a Flaherty, Keith T $u Massachusetts General Hospital, Boston, MA, USA
- 773 0_
- $w MED00009626 $t European journal of cancer (Oxford, England : 1990) $x 1879-0852 $g Roč. 160, č. - (2022), s. 287-288
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34756500 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20220107 $b ABA008
- 991 __
- $a 20220112153439 $b ABA008
- 999 __
- $a ind $b bmc $g 1745328 $s 1152138
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 160 $c - $d 287-288 $e 20211028 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
- LZP __
- $a Pubmed-20220107